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are associated with type 1 diabetes and coronary
artery calcification
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Background: Advanced glycation endproducts (AGEs) may play a role in the development of coronary artery
calcification (CAC) in type 1 diabetes (T1DM). We studied plasma AGEs in association with T1DM and CAC, and
whether or not the latter association could be explained by low-grade inflammation (LGI) or endothelial
dysfunction (ED).
Methods: We studied 165 individuals with and 169 without T1DM. CAC was quantified in a CAC score based on
CT-scanning. Plasma levels of protein-bound pentosidine, Nε-(carboxymethyl)lysine (CML) and Nε-(carboxyethyl)
lysine (CEL) were measured with HPLC/UPLC with fluorescence detection or tandem-mass spectrometry.
Tetrahydropyrimidine (THP) was measured with ELISA, as were HsCRP, and sVCAM-1 and vWF, as markers for LGI
and ED, respectively. Associations were analyzed with ANCOVA and adjusted for age, sex, BMI, waist-to-hip ratio,
smoking, blood pressure, lipid profile, eGFR and T1DM.
Results: Individuals with T1DM had higher plasma levels of pentosidine, CML and THP compared with controls;
means (95% CI) were 0.69 (0.65-0.73) vs. 0.51 (0.48-0.54) nmol/mmol LYS, p < 0.001; 105 (102–107) vs. 93 (90–95)
nmol/mmol LYS, p < 0.001; and 126 (118–134) vs. 113 (106–120) U/mL, p = 0.03, respectively. Levels of pentosidine
were higher in individuals with T1DM with a moderate to high compared with a low CAC score, means (95% CI)
were 0.81 (0.70-0.93) vs. 0.67 (0.63-0.71) nmol/mmol LYS, p = 0.03, respectively. This difference was not attenuated
by adjustment for LGI or ED.
Conclusions: We found a positive association between pentosidine and CAC in T1DM. These results may indicate
that AGEs are possibly involved in the development of CAC in individuals with T1DM.
Keywords: Advanced glycation endproducts, Coronary artery calcification, Type 1 diabetesBackground
Individuals with type 1 diabetes mellitus (T1DM) have an
increased risk of cardiovascular disease (CVD) [1]. Ad-
vanced glycation endproducts (AGEs), which are formed
by a nonenzymatic reaction between reducing sugars and
proteins, are thought to play an important role in the de-
velopment of CVD in T1DM [2,3]. AGEs are able to affect
cell function via intracellular glycation of proteins, altering* Correspondence: c.schalkwijk@maastrichtuniversity.nl
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reproduction in any medium, provided the ortheir function [2], via cross-linking of extracellular matrix
proteins in large arteries, resulting in arterial stiffness [4],
and by binding to the receptor for AGEs (RAGE), indu-
cing receptor-mediated cell activation [5,6]. Well-studied
AGEs are the cross-link AGE, pentosidine, and Nε-(car-
boxymethyl)lysine (CML), i.e. a ligand for RAGE. More
recently, methylglyoxal (MGO) has gained increased at-
tention as being the most important precursor of rapid
intracellular production of AGEs [2,7]. MGO primarily re-
acts with arginine to form 5-hydro-5-methylimidazolone
(MG-H1), tetrahydropyrimidine (THP) and argpyrimidine,
and with lysine to form Nε (carboxyethyl)lysine (CEL) and
methylglyoxal lysine dimer (MOLD) [8,9].tral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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between individuals with and without T1DM are scarce.
So far, most of them are based on relatively small patient
and control groups [10,11], have used non-specific im-
munological techniques for the detection of AGEs [12,13]
or concentrate on individuals with T1DM only. In indi-
viduals with T1DM, we recently demonstrated that
plasma AGEs are positively associated with incident
fatal and nonfatal CVD, independent of cardiovascular
risk factors [3].
Coronary artery calcification (CAC) is a well-accepted
early marker and precursor of CVD [14,15] and correlated
with total atheroma burden. Individuals with T1DM have
been shown to have more coronary CAC [16,17]. In indi-
viduals with kidney disease, the AGE pentosidine and the
AGE-RAGE axis have been associated with arterial calcifi-
cation [14,18]. In addition, experimental studies recently
demonstrated that AGEs are able to induce vascular
calcification [19-23]. However, no study has previously
investigated the association of plasma AGEs with CAC in
individuals with T1DM. We hypothesised that AGEs
could lead to CVD either by increasing CAC directly or
more indirectly by increasing the atherosclerotic process
in individuals with T1DM. Potential mechanisms through
which AGEs could lead to the development of CAC are
via low-grade inflammation (LGI) and endothelial dys-
function (ED), which are both associated with higher AGE
levels [3].
In view of the above, the aims of this study were to
examine, first, whether plasma levels of the AGEs pento-
sidine, CML, CEL and THP are higher in a large sample
of individuals with T1DM, compared to controls; second,
if these AGEs are associated with CAC in individuals
with T1DM; and third, to which extent the association
of AGEs with CAC could be explained (i.e. mediated) by
markers of LGI and ED.
Methods
Study population and design
In 1998, a random sample of 199 men and women with
T1DM aged 30 to 55 years was taken from the diabetes
registers of five London hospitals. T1DM was defined by
age of onset ≤ 25 years and insulin treatment within one
year of diagnosis. A random sample of 201 individuals
from the general population, stratified to have a similar
age and gender distribution to the group with diabetes,
was drawn from the lists of two London general practices.
It was confirmed that these individuals had no clinical his-
tory of diabetes and were not on any treatment for dia-
betes. Participants were included regardless of any history
of heart disease. One participant (a woman with diabetes)
had a history of angina; none had had a myocardial infarc-
tion. Pregnant women and patients on renal replacement
therapy were excluded. Ethics Committee approval wasobtained. All participants gave informed written consent
prior to participation, having received full details of the
study procedures. Further details of this study have been
described elsewhere [16]. Individuals with missing data on
plasma AGEs (n = 48) or on any of the potential con-
founders (n = 18), i.e. on triglycerides (n = 13), HDL (n =
1), LDL (n = 18) or eGFR (n = 1), were excluded from our
analyses. Individuals with incomplete data did not materi-
ally differ in baseline characteristics from individuals with
complete data, except for the percentage of individuals
with a CAC score >10. We excluded 22 individuals with a
CAC score >10 because of missing data on AGEs (n = 20),
or potential confounders (n = 2). The complete case
analysis included 165 individuals with and 169 without
T1DM (n = 334).
Analysis of protein bound AGEs and lysine in plasma
Plasma AGEs were measured in EDTA samples obtained
from fasting venous blood, which were stored at −80°C
until analysis. Protein-bound pentosidine was quantified
using HPLC with fluorescence detection, as described in
detail elsewhere [24]. Intra- and interassay coefficients of
variation (CVs), as analysed in this study, for pentosidine
were 3.8 and 6.9%, respectively. Protein-bound CML, CEL
and lysine were quantified using UPLC MS/MS [25].
Intra- and interassay CVs were 4.5 and 3.4% for CML, 5.4
and 18.1% for CEL and 5.0 and 5.0% for lysine, respect-
ively. THP was measured using competitive ELISA [26].
Intra- and interassay variations were 5% and 8%, respect-
ively. Concentrations of protein-bound pentosidine, CML
and CEL were adjusted for levels of lysine and expressed
as nmol/mmol lysine.
EBCT scan
An Ultrafast CT scanner (IMATRON C-150XL) was used
to quantify coronary calcification. Two sets of 20 trans-
verse tomograms of 3-mm thickness were obtained from
the lower margin of the bifurcation of the right branch of
the pulmonary artery to the apex of the heart with breath
holding of the individual. A radiologist placed a region of
interest around each potentially calcific lesion (peak dens-
ity <130 Hounsfield U) within the right coronary, circum-
flex, left anterior descending and left main coronary
arteries. The area and peak density of each lesion was
measured. A density score of 1 to 4 was defined based on
the peak density of the lesion; the calcification score was
then calculated as the product of the area of the lesion
and its density score as described by Agatston et al. [27].
To be included in the calcification score a lesion had to
have an area of at least 0.51 mm2, i.e., two contiguous
pixels and a peak density of at least 130 Hounsfield U. A
total score for each artery and for the entire heart was cal-
culated by summing the lesion scores. The radiation ex-
posure was <1 mSv. All scans were scored by the same
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betes status of the individual. Based on a small repeatabil-
ity study (n = 20) the within-observer agreement for the
presence of any calcification was high (kappa = 0.84).
Coronary artery calcification score
The cut-off value of 10 for the CAC score was based on
a recent review and meta-analysis on the validation of
electron beam computed tomography for coronary ar-
tery disease in both symptomatic and asymptomatic in-
dividuals [28]. In this review, the CAC score was divided
in three groups: low (0–10), moderate (10–400) and high
(>400). Since only 3 individuals had a CAC score above
400, the CAC score was analysed dichotomously com-
paring individuals with a CAC score of 0–10 (low) to in-
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Data are presented as mean ± standard deviation (SD), in case of a normal distribut
distribution of data, unless otherwise indicated.
HbA1c, glycated hemoglobin; BMI, body mass index; HDL, high-density lipoprotein;
Glomerular Filtration Rate by abbreviated Modification of Diet in Renal Disease equ
protein; sVCAM-1, soluble vascular cell adhesion molecule 1; vWF, von Willebrand F
lysine; THP, tetrahydropyrimidine.Covariates
Glomerular filtration rate (eGFR) was estimated according
to the short Modification of Diet in Renal Disease equa-
tion (MDRD) = 186* [serum creatinine (mg/dL)]-1.154* [age
(y)]-0.203* [0.742 if patient is female] [29]. Measurement of
creatinine was based on the enzymatic method. HbA1c,
systolic and diastolic blood pressure, total cholesterol,
HDL and LDL cholesterol and triglycerides were mea-
sured as described elsewhere [16]. High-sensitivity C-
reactive protein (hsCRP), a marker of LGI, was measured
with a highly sensitive in-house ELISA, as described previ-
ously [30]. A commercially available ELISA kit was used
to measure plasma soluble vascular cell adhesion molecule
1 (sVCAM-1) (R&D Systems). Von Willebrand factor
(vWF) activity was measured in heparin plasma by Shield
vWF activity ELISA kit (Shield Diagnostics Ltd, Dundee,tion study (CACS)
ntrols (n = 169) T1DM (n = 165) p-value
38.0 ± 3.8 37.8 ± 4.3 0.75
72/97 83/82 0.16
- 23.5 ± 7.6 -
5.31 ± 0.42 8.83 ± 1.53 <0.001
84 (50) 75 (46) 0.44
8.6 [3.5-17.0] 10.0 [4.5-18.0] 0.87
25.2 ± 4.5 25.4 ± 3.6 0.53
0.85 ± 0.08 0.87 ± 0.08 0.14
5.35 ± 1.02 5.32 ± 1.06 0.75
1.73 ± 0.40 1.84 ± 0.47 0.02
3.07 ± 0.93 2.95 ± 0.93 0.24
.06 [0.76-1.44] 0.97 [0.77-1.35] 0.37
117 ± 14 124 ± 14 <0.001
72 ± 10 73 ± 9 0.22
89 ± 16 97 ± 15 <0.001
0.0 [0.0-1.0] 1.0 [0.0-5.0] <0.001
2 (1) 30 (18) <0.001
.84 [0.43-1.76] 1.04 [0.46-2.87] 0.02
85 [820–1175] 1161 [964–1374] <0.001
87 [65–108] 97 [72–126] <0.01
.48 [0.41-0.58] 0.65 [0.55-0.81] <0.001
92.5 ± 15.7 104.6 ± 19.4 <0.001
14.5 ± 3.2 15.1 ± 3.7 0.12
0.0 [94.0-123.2] 117.8 [102.9-135.4] 0.02
ion of data, or as median [inter quartile range (IQR)], in case of a skewed
LDL, low-density lipoprotein; BP, blood pressure; eGFRMDRD, estimated
ation; CAC, coronary artery calcification; hsCRP, high sensitivity C-reactive
actor; CML, N(epsilon)-(carboxymethyl)lysine; CEL, N(epsilon)-(carboxyethyl)
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as percentage of vWF in pooled plasma of healthy volun-
teers. sVCAM-1 and vWF were considered markers of
ED.
Statistical methods
Analyses were carried out using SPSS version 20 for
Windows. Comparisons of baseline characteristics be-
tween groups were made by use of a Student’s t or χ2
tests. In Table 1, in case of CAC score levels, compari-
sons were made by use of a Mann–Whitney U test. We
performed complete case analyses. ANCOVA was used
to identify the differences in levels of plasma AGEs be-
tween individuals with and without T1DM and with and
without a CAC score >10. Variables with a skewed dis-
tribution (e.g. plasma pentosidine and THP) were log10-
transformed, and transformed back to provide geometric
means. We investigated whether the associations of
AGEs with CAC differed between men and women by
adding interaction terms to the models. Finally, linear
regression analysis was used to evaluate to what extent
LGI and ED mediated the association of AGEs with
CAC in individuals with T1DM. The percentage change
in the magnitude of the linear regression coefficient be-
tween the model with or without LGI and/or ED reflects
to what extent the association could be explained by me-
diation. P-values <0.05 were considered statistically signifi-
cant, except for interaction terms, where a p-value <0.10
was considered statistically significant.
Results
Table 1 shows the general characteristics of the study
population. HbA1c levels were higher in individuals with
T1DM, as were HDL cholesterol, systolic blood pressure
(SBP), eGFR, hsCRP, sVCAM-1 and vWF. The percent-
age of individuals with a CAC score >10, compared to
0–10, was higher in T1DM than in controls; only twoTable 2 Plasma AGE-levels in individuals with and without T1
Mod
Mean 95%
Pentosidine* (nmol/mmol LYS) control 0.51 0.48 –
T1DM 0.69 0.65 –
CML (nmol/mmol LYS) control 92.3 89.6 –
T1DM 104.8 102.1 –
CEL (nmol/mmol LYS) control 14.5 14.0 –
T1DM 15.0 14.5 –
THP* (U/mL) control 112.7 106.2 –
T1DM 125.6 118.0 –
Data are presented as adjusted means or geometric means* of AGEs in individuals
n = 169 for individuals without and n = 165 for individuals with T1DM.
Model 1 was adjusted for age and sex. Model 2 was adjusted for age, sex, SBP, DBP
CML, N(epsilon)-(carboxymethyl)lysine; CEL, N(epsilon)-(carboxyethyl)lysine; THP, tetindividuals without T1DM had a CAC score >10, whereas
32 individuals with T1DM had a CAC score >10 (Table 1).
Plasma AGEs in individuals with and without T1DM
Plasma levels of the AGEs pentosidine, CML and THP
were significantly higher in individuals with T1DM com-
pared to controls (Table 1). Plasma levels of pentosidine,
CML and THP remained significantly higher in individ-
uals with T1DM after adjustment for age and sex and
additional adjustment for systolic and diastolic blood
pressure, body mass index (BMI), waist to hip ratio
(WHR), smoking, LDL and HDL cholesterol, triglycer-
ides and eGFR (Table 2). In individuals with T1DM,
none of the plasma AGEs were significantly associated
with HbA1c or diabetes duration (data not shown).
Plasma AGEs in individuals with T1DM and a low or
moderate to high coronary artery calcification score
The associations of AGEs with CAC were analysed in
T1DM only, due to the low number of individuals with
a CAC score >10 in the control group. We performed a
complete case analysis in the 165 individuals with
T1DM, of whom 135 had a CAC score of 0–10 and 30
had a score >10. The associations of AGEs with the CAC
score did not significantly differ between men and women;
therefore we presented the results for men and women
combined. Plasma levels of the AGE pentosidine were
significantly higher in individuals with a CAC score >10
compared to those with a score of 0–10 after adjustment
for age and sex, while levels of CML, CEL and THP were
similar (Table 3). After additional adjustment for systolic
and diastolic blood pressure, BMI, WHR, smoking, LDL
and HDL cholesterol, triglycerides and eGFR, plasma
pentosidine levels remained significantly higher in individ-
uals with a CAC score >10 (Table 3). Additional adjust-
ment for HbA1c level and diabetes duration did not
materially change these results. The association of plasmaDM
el 1 Model 2
-CI p-value Mean 95%-CI p-value
0.53 0.51 0.48 – 0.54
0.73 <0.001 0.69 0.65 – 0.73 <0.001
94.9 92.6 90.1 – 95.1
107.5 <0.001 104.5 102.0 – 107.0 <0.001
15.0 14.6 14.1 – 15.2
15.5 0.212 14.9 14.4 – 15.4 0.489
119.7 112.7 105.7 – 119.9
133.4 0.015 125.6 117.8 – 134.0 0.025
with and without T1DM, by use of a complete case analysis.
, BMI, WHR, pack-years of smoking, LDL, HDL, triglycerides and eGFR.
rahydropyrimidine.
Table 3 Plasma AGE-levels in individuals with T1DM and a moderate to high compared with a low CAC score
Model 1 Model 2
Mean 95%-CI p-value Mean 95%-CI p-value
Pentosidine* (nmol/mmol LYS) CAC = 0-10 0.67 0.63 – 0.72 0.67 0.63 – 0.71
CAC > 10 0.80 0.69 – 0.92 0.034 0.81 0.70 – 0.93 0.028
CML (nmol/mmol LYS) CAC = 0-10 105.0 101.7 – 108.2 104.5 101.5 – 107.5
CAC > 10 102.9 95.8 – 110.0 0.608 105.0 98.3 – 111.8 0.883
CEL (nmol/mmol LYS) CAC = 0-10 14.9 14.2 – 15.5 14.9 14.3 – 15.5
CAC > 10 15.9 14.6 – 17.3 0.166 15.9 14.6 – 17.3 0.163
THP* (U/mL) CAC = 0-10 122.2 113.5 – 131.8 121.6 112.7 – 131.2
CAC > 10 140.6 119.4 – 165.6 0.131 143.9 121.3 – 170.6 0.086
Data are presented as adjusted means or geometric means* of AGEs in individuals with a CAC score of 0–10 compared to >10 in individuals with T1DM, by use of
a complete case analysis.
n = 135 for individuals with a calcification score of 0–10; n = 30 for individuals with a calcification score of >10.
Model 1 was adjusted for age and sex. Model 2 was adjusted for age, sex, SBP, DBP, BMI, WHR, pack-years of smoking, LDL, HDL, triglycerides and eGFR.
CML, N(epsilon)-(carboxymethyl)lysine; CEL, N(epsilon)-(carboxyethyl)lysine; THP, tetrahydropyrimidine.
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mediated) by LGI or ED (Table 4).
Discussion
Our study had three main findings. First, we found
higher plasma levels of the AGEs pentosidine, CML and
THP in individuals with T1DM. Second, the AGE pentosi-
dine was positively associated with CAC, an early marker
of CVD. Third, the association of pentosidine with CAC
was not explained by markers of LGI or ED.
Plasma AGEs in type 1 diabetes
This is the first larger study that has quantified multiple
plasma AGEs with state-of-the-art ultra-performance li-
quid chromatography (UPLC) in combination with tan-
dem mass spectrometry or, in case of pentosidine, with
high-performance liquid chromatography (HPLC) and
fluorescence detection. These techniques are considered
to be the most accurate techniques for the measurement
of AGEs at this moment. Unfortunately, because of acid
instability of THP, it was not possible to measure THP
with these techniques and therefore THP was measured
with an ELISA. We investigated four out of many different
AGEs and found that plasma levels of the AGEs pentosi-
dine, CML and THP were significantly higher in individ-
uals with T1DM as compared to controls, independent ofTable 4 Mediation analyses of the association of plasma pent
inflammation and endothelial dysfunction in T1DM
Model 2
Standardised β 95%-CI p-value Standardise
Pentosidine (SD) 0.47 0.03 – 0.91 0.036 0.47
Data are presented as standardized β (sβ). A sβ of 0.47 SD indicates that individuals
pentosidine levels compared to individuals with a score of 0–10.
n = 122 for individuals with a calcification score of 0–10; n = 27 for those with a calc
Model 2 was adjusted for age, sex, SBP, DBP, BMI, WHR, pack-years of smoking, LDL
sensitivity C-reactive protein (hsCRP), a marker for low-grade inflammation (LGI), or
Factor (vWF), which are markers of endothelial dysfunction (ED).age, sex, systolic and diastolic blood pressure, BMI, WHR,
smoking, LDL and HDL cholesterol, triglycerides and
eGFR. Levels of CEL were not statistically different. These
results are in agreement with previous studies which were
confined to small study populations [10,11] and/or have
used non-specific immunological techniques for the de-
tection of AGEs [12,13].
We did not find any association of plasma AGEs with
HbA1c in the individuals with T1DM. These findings are
consistent with many other studies that reported no as-
sociation of plasma AGEs with HbA1c [31-35]. An ex-
planation for this lack of association could be that AGEs
can also be formed through other pathways, for example
lipid peroxidation, besides glucose metabolism. More-
over, HbA1c and AGEs presumably reflect different
pathways following hyperglycaemia and different time-
frames of hyperglycaemia.
Associations between plasma AGEs and CAC in type 1
diabetes
We and others have previously shown that the preva-
lence of CAC is increased in T1DM [16,17]. In individ-
uals with kidney disease, the AGE pentosidine and the
AGE-RAGE axis have been associated with arterial calci-
fication [14,18]. This is the first study that has examined
the association of plasma AGEs with CAC in T1DM.osidine levels with the CAC score by low grade
Model 2 + LGI Model 2 + ED
d β 95%-CI p-value Standardised β 95%-CI p-value
0.03 – 0.91 0.038 0.43 −0.02 – 0.87 0.060
with T1DM with a CAC score of >10 have on average 0.47 SD higher
ification score of >10.
, HDL, triglycerides and eGFR. This model was additionally adjusted for high
for soluble vascular cell adhesion molecule 1 (sVCAM-1) and von Willebrand
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but not CML, CEL and THP, in individuals with T1DM
with a moderate to high compared to a low CAC score.
These results are in line with a previous study that re-
ported an independent positive association of pentosi-
dine with CAC in individuals undergoing hemodialysis
[14], while no association was found between CML and
CAC. Moreover, Conway et al. and Orchard et al. showed
that skin autofluorescence, as a possible reflectance of tis-
sue AGE accumulation, was associated with CAC severity
in T1DM [36,37].
Potential mechanisms underlying the associations
between AGEs and CAC
In contrast to the positive association of pentosidine
with CAC, CML, CEL and THP were not associated
with CAC. This could indicate that plasma pentosidine
is a better reflection of total AGE formation than these
other AGEs or that it is more precisely quantified with
current methods. Alternatively, pentosidine differs from
the other AGEs measured because it is known as a
cross-linking AGE [4,38], and it might be that cross-
linking AGEs in particular are linked to CAC. THP was
borderline significantly associated with CAC (p = 0.09).
THP is one of the AGEs, next to CEL, which is formed
from the reaction of the reactive dicarbonyl MGO with
arginine or lysine, respectively, predominantly formed
from intracellular glycation [2]. Little is known about
THP, but it could represent a better reflection of intracel-
lular MGO-AGEs than CEL. Moreover, auto-antibodies
against MGO-modified apolipoprotein B100 have been
found to be inversely associated with CAC in patients with
type 2 diabetes [39], also indicating a role of MGO in
CAC. Therefore, if our results indeed reflect a causal link
between AGEs and CAC, this might mean that cross-
linking or intracellular glycation via MGO may stimulate
the process of arterial calcification. The fact that we did
find an association of pentosidine and THP with CAC in
individuals with T1DM who were relatively young and
had an early stage of CAC may indicate that increased
levels of these AGEs are associated with early develop-
ment of CAC. However, overall, our numbers of individ-
uals with substantial calcification in the study are low,
probably partially due to the relatively young age of the
participants, which is why these analyses should be repli-
cated in larger cohorts.
AGEs are able to induce LGI and ED [3,5,40], and
markers of these processes are associated with coronary
or carotid artery disease in T1DM [41,42]. We demon-
strated that the association of pentosidine with CAC was
not explained (i.e. mediated) by LGI or ED. Other stud-
ies that investigated the mediating effect of LGI and ED
in the association of AGEs with CVD in T1DM [3,43] also
found no mediating effect of either of these potentialmechanisms. Therefore, other mechanisms besides LGI
and ED might be involved in the association of AGEs with
CAC. Recent publications show that AGEs-induced vas-
cular calcification in rat vascular smooth muscle cells
(VSMCs) is mediated by oxidative stress in vitro [44,45],
and oxidative stress may thus provide an additional mech-
anism explaining the association of AGEs with CAC.
The association between pentosidine and CAC might
be causal since experimental studies have demonstrated
a direct link of AGEs with calcification [21]. In response
to AGEs, aortic VSMCs differentiate into cells that exhibit
an osteoblast-like phenotype characterized by the depos-
ition of calcium into the extracellular matrix [19,20].
These findings support a direct role of AGEs in the stimu-
lation of CAC. Furthermore, the AGE-RAGE axis has
been associated with arterial calcification in animal studies
[22,23]. However, in our study, we did not find an associ-
ation between CML, a known ligand for RAGE, and CAC.
Another pathway by which AGEs are thought to contrib-
ute to atherosclerosis is by the stimulation of apoptosis of
endothelial progenitor cells (EPCs) and by the impairment
of EPC functions [46,47]. Indeed, skin autofluorescence,
an estimate of tissue AGE accumulation, has been nega-
tively associated with circulating EPCs [48]. Furthermore,
low levels of EPCs have been shown to be an independent
determinant of carotid intima media thickness (cIMT) in
young individuals with T1DM [49]. Interestingly, in indi-
viduals with compared to those without coronary athero-
sclerosis, it was found that a higher percentage of EPCs
express the osteoblastic marker osteocalcin (OCN) [50],
which has been shown to correlate with markers of bone
formation [51]. Therefore, a particular subset of EPCs has
been suggested to mediate abnormal vascular repair and
vascular calcification [52].
Limitations of our study
Our study had a cross-sectional design; therefore we can-
not draw any conclusions about causality in the associ-
ation of AGEs with T1DM and CAC. Because not all
atherosclerotic plaques contain calcium, the CAC score
does not take non-atherosclerotic plaques into account.
Despite this caveat, it has been shown that CAC is highly
associated with total coronary atherosclerotic plaque
burden [53]. Additionally, individuals with diabetes are
known to have a higher prevalence of medial calcification
of the peripheral vessels. However, medial calcification of
the coronary tree, not caused by atherosclerosis, is not
very common in diabetes [54]. It therefore seems likely
that the CAC score measured in our study indeed reflects
intima calcification associated with atherosclerosis.
We cannot discard the possibility that the use of a sin-
gle or a selection of markers representing LGI and ED,
respectively, may have led to an underestimation of their
mediating effects in the association of AGEs with CAC.
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idated markers and is thought to represent overall LGI.
Furthermore, hsCRP is known to be associated with cor-
onary heart disease [55]. sVCAM-1 and vWF are well
known markers of ED [56].
Conclusions
In conclusion, we found higher plasma levels of the AGEs
pentosidine, CML and THP in individuals with compared
to without T1DM, independent of age, sex, body mass
index, waist-to-hip ratio, smoking, blood pressure, lipid
profile and glomerular filtration rate. Pentosidine levels
were higher in individuals with T1DM with a moderate to
high compared to a low CAC score, independent of age,
sex, body mass index, waist-to-hip ratio, smoking, blood
pressure, lipid profile and glomerular filtration rate. The
association of pentosidine with CAC was not explained
(i.e. mediated) by LGI or ED. These results may indicate
that AGEs are involved in the development of CAC in
T1DM, but future studies are needed to fully elucidate the
direction and potential causality of this relationship. If
AGEs indeed play a role in the early development of cor-
onary artery calcification in T1DM, they could be an early
target for the prevention of CVD.
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